{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:50:24Z","timestamp":1761745824536},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11596-023-2791-9","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:02:49Z","timestamp":1695798169000},"page":"1206-1212","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhi-li","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-zhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-bing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"8","key":"2791_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","volume":"134","author":"F Valk","year":"2016","unstructured":"Valk F, Bekkering S, Kroon J, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016,134(8):611\u2013624","journal-title":"Circulation"},{"issue":"23","key":"2791_CR2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, John CM, Kausik R, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010,31(23):2844\u20132853","journal-title":"Eur Heart J"},{"issue":"26","key":"2791_CR3","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"JF Peden","year":"2009","unstructured":"Peden JF, Hopewell J, Clarke R. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009,361(26):2518\u20132528","journal-title":"N Engl J Med"},{"key":"2791_CR4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"Kamstrup","year":"2009","unstructured":"Kamstrup, Pia R, Tyb\u00e6rg-Hansen, et al. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 2009,301:2331\u20132339","journal-title":"JAMA"},{"issue":"12","key":"2791_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","volume":"49","author":"G Patti","year":"2007","unstructured":"Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007,49(12):1272\u20131278","journal-title":"J Am Coll Cardiol"},{"key":"2791_CR6","doi-asserted-by":"crossref","unstructured":"Zheng B, Jiang J, Liu H, et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP. Eur Heart J Suppl, 2015(suppl_B):B47\u2013B56","DOI":"10.1093\/eurheartj\/suv021"},{"issue":"5","key":"2791_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jjcc.2013.09.012","volume":"63","author":"Y Jang","year":"2014","unstructured":"Jang Y, Zhu J, Ge J, et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-na\u00efve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol, 2014,63(5):335\u2013343","journal-title":"J Cardiol"},{"issue":"13","key":"2791_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.2018.2444","volume":"319","author":"O Berwanger","year":"2018","unstructured":"Berwanger O, Santucci EV, de Barros E Silva PGM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 2018,319(13):1331\u20131340","journal-title":"JAMA"},{"key":"2791_CR9","doi-asserted-by":"crossref","unstructured":"Zheng W, Zhang YJ, Bu XT, et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore), 201,96(46):e8555","DOI":"10.1097\/MD.0000000000008555"},{"key":"2791_CR10","unstructured":"Fran\u00e7ois M, Colin B, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J, 2019(1):1"},{"key":"2791_CR11","unstructured":"Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients. Chin J Cardiol (Chinese), 2020,48(4):280\u2013286"},{"key":"2791_CR12","unstructured":"China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019). Chin J Intern Med (Chinese), 2019,59(1):18\u201322"},{"issue":"04","key":"2791_CR13","first-page":"258","volume":"48","author":"W Yongjun","year":"2015","unstructured":"Yongjun W, Chunxue W, Zhongrong M. Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack 2014. Chin J Neurol (Chinese), 2015,48(04):258\u2013273","journal-title":"Chin J Neurol (Chinese)"},{"key":"2791_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med, 2014,370:1809\u20131819","journal-title":"N Engl J Med"},{"issue":"20","key":"2791_CR15","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"A Kck","year":"2019","unstructured":"Kck A, Sw A, Gp B, et al. Evolocumab for Early Reduction of LDLCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol, 2019,74(20):2452\u20132462","journal-title":"J Am Coll Cardiol"},{"key":"2791_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","volume":"142","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Blaha MJ, Jones SR, et al. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation, 2020,142:419\u2013421","journal-title":"Circulation"},{"issue":"17","key":"2791_CR17","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","volume":"74","author":"A Mjk","year":"2019","unstructured":"Mjk A, Mss B, Rpgs B, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol, 2019,74(17):2132\u20132146","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2791_CR18","first-page":"261","volume":"18","author":"YQ Liu","year":"2021","unstructured":"Liu YQ, Li DD, Chai M, et al. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). J Gerratr Cardiol, 2021,18(4):261\u2013270","journal-title":"J Gerratr Cardiol"},{"key":"2791_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation, 2019,139:1483\u20131492","journal-title":"Circulation"},{"issue":"7","key":"2791_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol, 2022,7(7):760\u2013769","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2791_CR21","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1194\/jlr.M078212","volume":"58","author":"B Enkhmaa","year":"2017","unstructured":"Enkhmaa B, Anuurad E, Zhang W, et al. The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab. J Lipid Res, 2017,58(10):2008\u20132016","journal-title":"J Lipid Res"},{"issue":"24","key":"2791_CR22","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Philip L, Gordts SM, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J, 2020,41(24):2275\u20132284","journal-title":"Eur Heart J"},{"issue":"4","key":"2791_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","volume":"135","author":"GF Watts","year":"2017","unstructured":"Watts GF, Chan DC, Dent R, et al. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation, 2017,135(4):338\u2013351","journal-title":"Circulation"},{"issue":"27","key":"2791_CR24","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","volume":"39","author":"GF Watts","year":"2018","unstructured":"Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J, 2018,39(27):2577\u20132585","journal-title":"Eur Heart J"},{"issue":"7","key":"2791_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","volume":"120","author":"M Sharma","year":"2017","unstructured":"Sharma M, Redpath GM, Williams MJA, et al. Recycling of Apolipoprotein(a) after PlgRKT-Mediated endocytosis of lipoprotein(a). Circ Res, 2017,120(7):1091\u20131102","journal-title":"Circ Res"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-023-2791-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T13:10:59Z","timestamp":1703769059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-023-2791-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1007\/s11596-023-2791-9","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest in this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}